Given how technology has become the increasingly unstoppable architect of our everyday lives – the world edging closer and closer to a Terminator prequel – it's not hard to immediately invest in a horror film about the all-consuming threat of artificial intelligence. The film industry itself has been losing ground as AI continues to provide a cheaper and easier alternative to those pesky humans and in a year of bleak headline after bleak headline, it should theoretically be perfect timing for Blumhouse's late August M3gan-adjacent chiller AfrAId. Yet, as one might be able to predict without the help of a digital forecast, easy targets are easily missed in a hokey and rushed jumble of half-ideas that's as gimmicky and eye-rollingly stupid as its title. In the dog days of summer, on a particularly rubbishy Labor Day weekend at the movies (other new releases include long-delayed sci-fi thriller Slingshot and a reverential biopic of Reagan), it's at least reassuring to know that very few people will find themselves stuck with this one (it's tracking to make between 5m and 7m). Sony, clearly scared of scaring off those precious few, decided not to provide a single press screening, aware of the critical drubbing this would receive. It's not quite as unreleasably awful as that strategy might suggest – it's competently, at times handsomely, shot, refreshingly dour and crucially not as awful as The Crow – but it's too sloppily written and edited for even the least discerning of horror fans to really enjoy, a patchwork of nonsense confusingly stitched together by someone, who at one point, knew better.

Artificial intelligence startup Data Skrive doesn't want to take jobs away from sports reporters--just free them from the statistical grind. What if I told you that most of the sports stories you'll read in the future will be written by robots? Well, actually, you probably already have perused a few AI-generated articles on athletics and didn't even realize it. The Hawaii baseball team pounded out 15 hits en route to a 13-6 rout of UC Davis today at Les Murakami Stadium. By winning two of this three-game set, the Rainbow Warriors won a series for the second time this season.

Efficiently and effectively identifying high-quality drug candidates for clinical development is challenging, even for large companies like Takeda that has extensive R&D expertise and therapeutic experience in the areas of oncology, gastroenterology, and diseases of the central nervous system. To combat this challenge, Takeda, not unlike others in the industry, is looking to augment its internal drug discovery abilities with innovative capabilities from outside the company – at pharma and bio companies, as well as academic institutions around the world. The search for partners with unique drug discovery capabilities prompted Takeda to enter into an alliance with Numerate. Numerate is a software company that has developed algorithms that analyze large amounts of data and find promising unexplored chemical space for the human drug targets Takeda wants to pursue. "They [Numerate] are able to leverage publicly available data as well as our proprietary data to computationally envision new chemical space for novel therapies," says David Weitz, Head of Takeda California and Global Research Externalization for Takeda California.